Core Insights - Nautilus Biotechnology, Inc. has selected Baylor College of Medicine as the first customer for its Nautilus Voyager™ Platform, which is part of an Early Access Program aimed at developing a computational multi-omics toolkit for cancer research [1][3] - The project, funded by the NIH, focuses on leveraging single-molecule proteomics to identify aberrant protein isoforms that play a role in tumor growth and therapeutic resistance [1][2] Group 1: Company Overview - Nautilus Biotechnology is a development stage life sciences company headquartered in Seattle, Washington, with a mission to democratize access to the proteome and advance human health and medicine [5] - The Nautilus Voyager™ Platform utilizes a proprietary Iterative Mapping approach to measure intact single-molecule proteins, accommodating up to 10 billion protein molecules for high-resolution analysis [4] Group 2: Research Collaboration - The study led by Baylor Professors Bing Zhang and Yongchao Dou aims to create a computational toolkit that enhances the detection of protein isoforms in conventional proteomics datasets [2] - The collaboration intends to provide a deeper understanding of cancer biology by integrating transcriptional and proteomic data at unprecedented resolution [2][3] Group 3: Technological Features - The Voyager Platform's design allows for rapid measurement of single-molecule proteins, with machine learning algorithms converting binding patterns into protein identifications [4] - The platform is user-friendly, designed for standard lab placement, and requires minimal facility requirements [4]

Core Insights - Nautilus Biotechnology, Inc. has appointed Amber Faust as Vice President of Sales to enhance the commercial progress of its Voyager Platform, which focuses on single-molecule proteome analysis [3][5][6] Company Developments - The Voyager Platform has recently been launched, featuring Iterative Mapping technology that allows for single-molecule analysis of proteins and proteoforms [3][5] - The company is preparing for the commercial launch of the Voyager Platform in late 2026, which includes securing pre-orders and managing installations [5][6] - The Nautilus Tau Proteoforms assay is currently in use at the Buck Institute for Research on Aging, mapping up to 768 distinct tau proteoform groups [5] Leadership and Expertise - Amber Faust brings nearly two decades of experience in life sciences, having held significant roles at companies like Olink Proteomics and SomaLogic [4][6] - Faust's background includes a Master of Science in Biomedical Science and a Bachelor of Science in Biology and Chemistry, emphasizing her expertise in the field [6] Technology Overview - The Voyager Platform utilizes a proprietary Iterative Mapping approach, capable of measuring up to 10 billion intact protein molecules, which allows for a wide dynamic range in analysis [7] - The platform employs machine learning algorithms to convert probe-binding patterns into protein and proteoform identifications, facilitating detailed analysis [7][8]

Core Insights - Nautilus Biotechnology, Inc. reported financial results for Q4 and fiscal year 2025, highlighting progress in platform development and commercialization efforts [1][3]. Financial Performance - Operating expenses for Q4 2025 were $15.4 million, a decrease of $4.6 million or 23% from $20.0 million in Q4 2024 [4]. - For the fiscal year 2025, operating expenses totaled $66.8 million, down $14.6 million or 18% from $81.5 million in 2024 [4]. - The net loss for Q4 2025 was $13.8 million, compared to a net loss of $17.6 million in Q4 2024 [5]. - The annual net loss for 2025 was $59.0 million, down from $70.8 million in 2024 [5]. - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $156.1 million [5]. Business Developments - The company is focusing on expanding its Early Access Program, starting with Tau proteoforms, to enhance customer engagement and technology validation [3][8]. - Nautilus launched the Iterative Mapping Early Access Program in January 2026, receiving positive initial feedback from academic, nonprofit, and biopharma partners [8]. - A collaboration supported by The Michael J. Fox Foundation aims to develop a proteoform-level assay for alpha-synuclein in Parkinson's disease research, expanding the platform's capabilities [8]. Future Outlook - For 2026, the company does not expect significant revenue from Early Access Program engagements and anticipates a 15-20% increase in operating expenses compared to 2025 [6]. - The company believes it has sufficient resources to fund operations through 2027 based on its cash position [6].

Core Insights - Nautilus Biotechnology, Inc. has launched the Voyager™ Platform, enabling the analysis of up to 10 billion intact proteins and proteoforms in a single run, enhancing next-generation proteomics across various research fields [3][4][5] Product Features - The Voyager Platform utilizes machine-learning powered analysis to identify and quantify intact protein molecules, featuring a user-friendly touchscreen interface and a benchtop design that does not require specialized lab facilities [4][5][13] - The platform's Iterative Mapping approach allows for rapid measurement of intact single-molecule proteins, accommodating a wide dynamic range and providing unique binding patterns for each molecule [5][13] Development and Testing - The Voyager Platform was successfully field-tested at the Buck Institute for Research on Aging, yielding novel insights into tau proteoform biology [4][10] - An Early Access Program was launched in January 2026, allowing researchers to utilize the platform's capabilities before its broader commercial availability expected in late 2026 [6][8] Applications and Impact - The initial offering of the Early Access Program includes the Nautilus Tau Proteoforms assay, which quantifies up to 768 full-length tau proteoform groups, critical for developing biomarkers and drug targets for neurodegenerative disorders like Alzheimer's disease [9][10] - The Voyager Platform aims to democratize access to proteomics, facilitating advancements in biomarker discovery, diagnostics, and therapeutic innovation [6][10] Future Presentations - Nautilus will present data on the Voyager Platform and its applications at the US HUPO 2026 conference, including sessions on tau proteoform analysis and large-scale proteoform detection capabilities [11][12]

Core Insights - Nautilus Biotechnology, Inc. has launched an Early Access Program for its novel proteomics platform, featuring a tau proteoforms assay aimed at accelerating Alzheimer's and neurodegenerative disease research [1][3][4] Group 1: Early Access Program - The Early Access Program allows select researchers to utilize Nautilus' Iterative Mapping method for protein analysis, enhancing the study of diseases like Alzheimer's [1][3] - Participants will receive support from Nautilus for data interpretation and analysis, facilitating rapid adoption and actionable insights [3][4] Group 2: Iterative Mapping Method - Nautilus' Iterative Mapping method enables single-molecule analysis of proteins, achieving comprehensive proteome coverage and detail, which is crucial for understanding post-translational modifications in diseases [2][4] - This method provides a high level of resolution, uncovering biological insights that traditional proteomics methods cannot achieve [2] Group 3: Commercialization and Research Collaboration - The Early Access Program marks a significant step towards commercialization, showcasing the platform's readiness for external use and future capabilities in proteomics [3][4] - Researchers at the Buck Institute for Research on Aging are already utilizing Nautilus' technology to map distinct tau proteoforms, revealing patterns associated with disease progression [5] Group 4: Custom Assays and Future Developments - The program also offers opportunities for exclusive development partnerships to create custom assays tailored to specific research needs [6] - Nautilus plans to host a webinar to discuss the benefits of Iterative Mapping and present updated research data, further promoting its platform [7]